U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C3H5NO2
Molecular Weight 87.0773
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of 2-OXAZOLIDINONE

SMILES

O=C1NCCO1

InChI

InChIKey=IZXIZTKNFFYFOF-UHFFFAOYSA-N
InChI=1S/C3H5NO2/c5-3-4-1-2-6-3/h1-2H2,(H,4,5)

HIDE SMILES / InChI

Molecular Formula C3H5NO2
Molecular Weight 87.0773
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Approval Year

PubMed

PubMed

TitleDatePubMed
Synthesis and biological evaluation of five-membered heterocycles fused to cyclopenta[c]thiophene as new antitumor agents.
2003-04-03
Chiral-auxiliary-controlled diastereoselectivity in the epoxidation of enecarbamates with DMD and mCPBA.
2003-03-20
Monoamine oxidases: to inhibit or not to inhibit.
2003-03
Comparison of nitration and oxidation of tyrosine in advanced human carotid plaque proteins.
2003-02-15
Asymmetric epoxidation catalyzed by N-aryl-substituted oxazolidinone-containing ketones: further evidence for electronic effects.
2003-02-06
Clinical experience with linezolid for the treatment of nocardia infection.
2003-02-01
Multicentre evaluation of the in vitro activity of linezolid in the Western Pacific.
2003-02
Concise stereocontrolled routes to fumagillol, fumagillin, and TNP-470.
2003-02
Linezolid: the first oxazolidinone antimicrobial.
2003-01-21
Identification of phenylisoxazolines as novel and viable antibacterial agents active against Gram-positive pathogens.
2003-01-16
Relationship between stereochemistry and the beta3-adrenoceptor agonistic activity of 4'-hydroxynorephedrine derivative as an agent for treatment of frequent urination and urinary incontinence.
2003-01-02
Synthesis and antibacterial activity of 5-substituted oxazolidinones.
2003-01-02
Linezolid: implications for neurosurgical infections.
2003-01
[Role of linezolid in antimicrobial therapy].
2003-01
Linezolid: an oxazolidinone antimicrobial agent.
2002-12-15
Multicentre assessment of linezolid antimicrobial activity and spectrum in Europe: report from the Zyvox antimicrobial potency study (ZAPS-Europe).
2002-12
Clinical failures of linezolid and implications for the clinical microbiology laboratory.
2002-12
Epoxyalcohol route to hydroxyethylene dipeptide isosteres. Stereodivergent synthesis of the diamino alcohol core of ritonavir and its C-2 epimer.
2002-11-29
A non-antibacterial oxazolidinone derivative that inhibits epithelial cell sheet migration.
2002-11-04
Linezolid-resistant enterococci: report of the first isolates in the United Kingdom.
2002-11
Virulence factor expression by Gram-positive cocci exposed to subinhibitory concentrations of linezolid.
2002-11
Design, synthesis, and evaluation of 4-(4'-aminobenzyl)-2-oxazolidinones as novel inhibitors of the cytochrome P-450 enzyme aromatase.
2002-10
Emerging linezolid-resistant Enterococcus faecalis and Enterococcus faecium isolated from two Austrian patients in the same intensive care unit.
2002-10
The protein synthesis inhibitors, oxazolidinones and chloramphenicol, cause extensive translational inaccuracy in vivo.
2002-09-13
First characterization of a cluster of VanA-type glycopeptide-resistant Enterococcus faecium, Colombia.
2002-09
Synthesis of conformationally constrained analogues of linezolid: structure-activity relationship (SAR) studies on selected novel tricyclic oxazolidinones.
2002-08-29
Regio- and stereoselective synthesis of (E)-alkene trans-Xaa-Pro dipeptide mimetics utilizing organocopper-mediated anti-S(N)2' reactions.
2002-08-23
Palladium-catalyzed aminoallylation of activated olefins with allylic halides and phthalimide.
2002-08-23
Synthesis of chiral pilocarpine analogues via a C-8 ketone intermediate.
2002-08-23
The synthesis and biological evaluation of a novel series of antimicrobials of the oxazolidinone class.
2002-08-19
Efficient asymmetric synthesis of (S)-2-ethylphenylpropanoic acid derivative, a selective agonist for human peroxisome proliferator-activated receptor alpha.
2002-08-19
[Prospects for development of new antituberculous drugs].
2002-08
Treatment of Staphylococcus epidermidis ventriculo-peritoneal shunt infection with linezolid.
2002-08
In vitro activity of AZD2563, a novel oxazolidinone, against European Gram-positive cocci.
2002-08
Highly diastereoselective dioxetane formation in the photooxygenation of enecarbamates with an oxazolidinone chiral auxiliary: steric control in the [2 + 2] cycloaddition of singlet oxygen through conformational alignment.
2002-07-31
Synthesis of sphingomyelin carbon analogues as sphingomyelinase inhibitors.
2002-07-12
Anti-anaerobic activity of AZD2563, a new oxazolidinone, compared with eight other agents.
2002-07
Antipneumococcal activity of AZD2563, a new oxazolidinone, compared with nine other agents.
2002-07
In vitro activity of a novel oxazolidinone, AZD2563, against randomly selected and multiresistant Gram-positive cocci.
2002-07
A new approach to (-)-swainsonine by ruthenium-catalyzed ring rearrangement.
2002-06-14
Novel oxazolidinone based compounds as inhibitors of aromatase and the use of the substrate-heme complex approach in the rationalisation of these compounds.
2002-06-07
AZD-2563 AstraZeneca.
2002-06
Comparative activity of linezolid against staphylococci and enterococci isolated in Italy.
2002-06
AZD2563, a new oxazolidinone: bactericidal activity and synergy studies combined with gentamicin or vancomycin against staphylococci and streptococcal strains.
2002-05
A multicenter evaluation of linezolid antimicrobial activity in North America.
2002-05
Spectrum and potency evaluation of a new oxazolidinone, linezolid: report from the SENTRY Antimicrobial Surveillance Program, 1998-2000.
2002-05
Novel agents for resistant Gram-positive infections--a review.
2002-03
[Linezolid--new antibacterial agent of the oxazolidinone group: its importance in the control of spreading and treatment of the multidrug resistance gram-positive infections].
2002
The discovery of linezolid, the first oxazolidinone antibacterial agent.
2001-08
Clinical trial results with linezolid, an oxazolidinone, in the treatment of soft tissue and postoperative gram-positive infections.
2001
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:59:08 GMT 2025
Edited
by admin
on Mon Mar 31 18:59:08 GMT 2025
Record UNII
Z4D49W92PP
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
NSC-35382
Preferred Name English
2-OXAZOLIDINONE
Systematic Name English
2-OXOTETRAHYDRO-1,3-OXAZOLE
Systematic Name English
1,3-OXAZOLIDIN-2-ONE
Systematic Name English
CARBAMIC ACID, (2-HYDROXYETHYL)-, .GAMMA.-LACTONE
Common Name English
OXAZOLIDINONE
Systematic Name English
NSC-38240
Code English
2-OXO-1,3-OXAZOLIDINE
Systematic Name English
2-OXAZOLIDONE
Systematic Name English
Code System Code Type Description
NSC
38240
Created by admin on Mon Mar 31 18:59:08 GMT 2025 , Edited by admin on Mon Mar 31 18:59:08 GMT 2025
PRIMARY
WIKIPEDIA
Oxazolidinone
Created by admin on Mon Mar 31 18:59:08 GMT 2025 , Edited by admin on Mon Mar 31 18:59:08 GMT 2025
PRIMARY
CHEBI
1237
Created by admin on Mon Mar 31 18:59:08 GMT 2025 , Edited by admin on Mon Mar 31 18:59:08 GMT 2025
PRIMARY
NSC
35382
Created by admin on Mon Mar 31 18:59:08 GMT 2025 , Edited by admin on Mon Mar 31 18:59:08 GMT 2025
PRIMARY
FDA UNII
Z4D49W92PP
Created by admin on Mon Mar 31 18:59:08 GMT 2025 , Edited by admin on Mon Mar 31 18:59:08 GMT 2025
PRIMARY
CAS
51667-26-6
Created by admin on Mon Mar 31 18:59:08 GMT 2025 , Edited by admin on Mon Mar 31 18:59:08 GMT 2025
NON-SPECIFIC SUBSTITUTION
CAS
497-25-6
Created by admin on Mon Mar 31 18:59:08 GMT 2025 , Edited by admin on Mon Mar 31 18:59:08 GMT 2025
PRIMARY
PUBCHEM
73949
Created by admin on Mon Mar 31 18:59:08 GMT 2025 , Edited by admin on Mon Mar 31 18:59:08 GMT 2025
PRIMARY
EPA CompTox
DTXSID2074326
Created by admin on Mon Mar 31 18:59:08 GMT 2025 , Edited by admin on Mon Mar 31 18:59:08 GMT 2025
PRIMARY
ECHA (EC/EINECS)
207-840-9
Created by admin on Mon Mar 31 18:59:08 GMT 2025 , Edited by admin on Mon Mar 31 18:59:08 GMT 2025
PRIMARY